All news articles for November 2020

© GettyImages/champc

October sees boost for biotech funding

By Jane Byrne

Biotech funding kicked back into higher gear in October, pushing toward the summer monthly record highs with $10.5B raised, writes analyst firm, Jefferies

J&J has now taken its COVID-19 vaccine into Phase 3 trials for both a 1-dose and 2-dose regimen. Pic:getty/JHDTstockimages

J&J launches Phase 3 trial for 2-dose COVID-19 vaccine

By Rachel Arthur

Johnson & Johnson has launched a second global Phase 3 trial for its Janssen COVID-19 vaccine candidate: this time exploring a 2-dose regimen (its existing Phase 3 trial is for a 1-dose regimen).

© GettyImages/surasaki

Top five stories from October

By Jane Byrne

COVID-19 is like a big oak tree casting shade on all other biopharma industry developments. Vaccine-related articles dominate the most popular story rankings. With Pfizer and BioNTech now out in front in the coronavirus vaccine race, we track the related...

Follow us

Products

View more

Webinars